| | Drug Name | Overall Survival without PBT | Overall Survival with PBT | Progression-Free Survival without PBT | Progression-Free Survival with PBT | Usefulness Rating | toxicity level | Toxicity Explanation |
|---|
| Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine | Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine | Historical controls suggest a median survival time of 6 months for recurrent GBM | Median survival of 42.6 weeks (~9.8 months) in recurrent GBM; Median survival of 23.8 months in newly diagnosed GBM when combined with the Stupp protocol | Typically less than 7 months for newly diagnosed GBM under standard treatment | 17.8 months for newly diagnosed GBM, possibly the longest PFS seen in a phase II trial for GBM | 4 | 2 | While specific side effects are not detailed, similar vaccines have been associated with manageable side effects like flu-like symptoms, suggesting a relatively low toxicity level. |
| Anti-CMV Dendritic Cell Vaccine | Anti-CMV Dendritic Cell Vaccine | Historical controls indicate median overall survival around 15-17 months for newly diagnosed GBM. | Varied; one study showed median OS of 41.1 months with vaccine and temozolomide, and another indicated 30.3 months with vaccine and basiliximod. | Typically around 6-7 months for standard GBM treatments. | Impressive 25.3 months in a study combining vaccine with dose-intense temozolomide. | 4 | 2 | Dendritic cell vaccines like this one are known for their favorable safety profile, with predominantly mild, manageable adverse effects. |
| Dendritic Cell Vaccine (DCVax-L) | Dendritic Cell Vaccine (DCVax-L) | Median overall survival for GBM is typically 15-17 months from diagnosis, or 8 months from recurrence | Median overall survival of 19.3 months from randomization (22.4 months from surgery) for newly diagnosed GBM patients; 13.2 months from relapse for recurrent GBM | Data not specified | Median progression-free survival of 6.2 months in the DCVax-L arm, compared to 7.6 months in the placebo group, though this difference was not statistically significant | 4 | 2 | Well-tolerated with very few serious adverse events related to the treatment, including cases of intracranial edema, nausea, and lymph node infection. No evidence of autoimmune reactions or cytokine storm. |
| Newcastle Disease Virus | Newcastle Disease Virus | Not specified | Not specified | Not specified | Not specified | Not rated | Not specified | Not specified |
| Rindopepimut (CDX-110) | Rindopepimut (CDX-110) | Median overall survival with standard treatment ranges around 15-17 months for newly diagnosed GBM | Phase III ACT IV trial did not show a significant increase in OS; however, a Phase II trial (ReACT) in recurrent GBM showed improved outcomes with bevacizumab | Standard treatments offer a median PFS of about 6.9 months | ReACT trial showed a 6-month PFS of 28% for the rindopepimut group compared to 16% for the control | 3 | 2 | Primarily associated with injection site reactions and overall shows a favorable safety profile |
| SL-701 | SL-701 (Immunotherapy Vaccine) | Historical controls suggest a median overall survival of 20-35% at 12 months for similar populations. | Stage 1 median overall survival was 11.0 months with a 12-month OS rate of 44%. Stage 2 showed a median OS of 11.7 months with a 12-month OS rate of 50%, suggesting an improvement over historical data. | Not specified | Data on progression-free survival specifically for SL-701 is under investigation; significant antitumor activity has been noted. | 4 | 2 | The vaccine's safety profile is characterized by the absence of severe adverse events, with only mild to moderate reactions observed, making it a potentially safer option for GBM treatment. |
| Wilms Tumor 1 (WT1) Peptide Vaccine | Wilms Tumor Peptide Vaccine | Varies depending on stage and treatment; typical survival rates for favorable histology are around 90% for localized disease | Median OS not reached for the vaccine group vs. 22.2 months for the placebo group; HR: 0.55 (95% CI: 0.35-0.87), p = 0.011 | Varies depending on stage and treatment | Median DFS of 11.9 months for the vaccine group vs. 5.6 months for the placebo group; HR: 0.52 (95% CI: 0.33-0.82), p = 0.005 | 4 | 2 | Generally well-tolerated with few serious adverse events; typical side effects are mild |
